The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?

Orphanet Journal of Rare Diseases

Benedikt Schoser¹  Robin Lachmann² 

[1] Friedrich-Baur Institut, Neurologische Klinik, Klinikum der Universität München, München, Germany;National Hospital for Neurology and Neurosurgery, London, UK

关键词: Outcome measures;    Minimal clinically important difference;    Late-onset Pompe disease;   

Others  :  863478
DOI  :  10.1186/1750-1172-8-160

 received in 2013-09-02, accepted in 2013-10-09,  发布年份 2013

【 摘 要 】

Pompe disease/glycogen storage disease type II, is a rare, lysosomal storage disorder associated with progressive proximal myopathy, causing a gradual loss of muscular function and respiratory insufficiency. Studies of patients with late-onset Pompe disease have used endpoints such as the 6-minute walking test (6MWT) and forced vital capacity (FVC) to assess muscular and respiratory function during disease progression or treatment. However, the relevance of these markers to late-onset Pompe disease and the minimal clinically important difference (MCID) for these endpoints in late-onset Pompe disease have not yet been established. A literature search was carried out to identify studies reporting the MCID (absolute and relative) for the 6MWT and FVC in other diseases. The MCIDs determined in studies of chronic respiratory diseases were used to analyze the results of clinical studies of enzyme replacement therapy in late-onset Pompe disease. In 9 of the 10 late-onset Pompe disease studies reviewed, changes from baseline in the 6MWT were above or within the MCID established in respiratory diseases. Clinical improvement was perceived by patients in 6 of the 10 studies. In 6 of the 9 late-onset Pompe disease studies that reported FVC, the changes from baseline in percentage predicted FVC were above or within the MCID established in respiratory diseases and the difference was perceived as either an improvement or stabilization by patients. However, applying the 6MWT and FVC MCIDs from studies of chronic respiratory diseases to late-onset Pompe disease has several important limitations. Outcome measures in muscular dystrophies include composite measures of muscle function and gait, as well as Rasch-designed and validated tools to assess disease-related quality of life and activities of daily living. Given that the relevance to patients with late-onset Pompe disease of the 6MWT or FVC MCIDs established for chronic respiratory diseases is unclear, these measures should be evaluated specifically in late-onset Pompe disease and alternative outcome measures more specific to neuromuscular disease considered.

【 授权许可】

   
2013 Lachmann and Schoser; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Ausems MG, Verbiest J, Hermans MP, Kroos MA, Beemer FA, Wokke JH, Sandkuijl LA, Reuser AJ, van der Ploeg AT: Frequency of glycogen storage disease type II in the Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 1999, 7:713-716.
• [2]Chien YH, Chiang SC, Zhang XK, Keutzer J, Lee NC, Huang AC, Chen CA, Wu MH, Huang PH, Tsai FJ, Chen YT, Hwu WL: Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program. Pediatrics 2008, 122:e39-e45.
• [3]Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom WN, Codd WJ, Hanna B, Alcabes P, Raben N, Plotz P: Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 1998, 79:69-72.
• [4]Schüller A, Wenninger S, Strigl-Pill N, Schoser B: Toward deconstructing the phenotype of late-onset Pompe disease. Am J Med Genet C Semin Med Genet 2012, 160:80-88.
• [5]van der Beek NA, de Vries JM, Hagemans ML, Hop WC, Kroos MA, Wokke JH, de Visser M, van Engelen BG, Kuks JB, van der Kooi AJ, Notermans NC, Faber KG, Verschuuren JJ, Reuser AJ, van der Ploeg AT, van Doorn PA: Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis 2012, 7:88. BioMed Central Full Text
• [6]Müller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, Walter MC, Baethmann M, Schlotter-Weigel B, Lochmüller H, Schoser B: Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 2007, 17:698-706.
• [7]Wokke JH, Escolar DM, Pestronk A, Jaffe KM, Carter GT, van den Berg LH, Florence JM, Mayhew J, Skrinar A, Corzo D, Laforet P: Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2008, 38:1236-1245.
• [8]Güngör D, de Vries JM, Hop WC, Reuser AJ, van Doorn PA, van der Ploeg AT, Hagemans ML: Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis 2011, 6:34. BioMed Central Full Text
• [9]Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, van der Ploeg AT: The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol 2005, 252:875-884.
• [10]Güngör D, Kruijshaar ME, Plug I, D’Agostino RB Sr, Hagemans ML, van Doorn PA, Reuser AJ, van der Ploeg AT: Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis 2013, 8:49. BioMed Central Full Text
• [11]Schneider I, Hanisch F, Müller T, Schmidt B, Zierz S: Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months. Wien Med Wochenschr 2013, 163:40-44.
• [12]Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, Moggio M, Filosto M, Sette E, Crescimanno G, Tonin P, Parini R, Morandi L, Marrosu G, Greco G, Musumeci O, Di Iorio G, Siciliano G, Donati MA, Carubbi F, Ermani M, Mongini T, Toscano A, Italian GSDII Group: Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 2012, 259:952-958.
• [13]Regnery C, Kornblum C, Hanisch F, Vielhaber S, Strigl-Pill N, Grunert B, Müller-Felber W, Glocker FX, Spranger M, Deschauer M, Mengel E, Schoser B: 36 Months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis 2012, 35:837-845.
• [14]van Capelle CI, van der Beek NA, Hagemans ML, Arts WF, Hop WC, Lee P, Jaeken J, Frohn-Mulder IM, Merkus PJ, Corzo D, Puga AC, Reuser AJ, van der Ploeg AT: Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul Disord 2010, 20:775-782.
• [15]van der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ, Kishnani PS, Laforêt P, Morgan C, Nations S, Pestronk A, Plotkin H, Rosenbloom BE, Sims KB, Tsao E: Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase Alfa. Mol Genet Metab 2012, 107:456-461.
• [16]ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.
• [17]Casanova C, Celli BR, Barria P, Casas A, Cote C, de Torres JP, Jardim J, Lopez MV, Marin JM, Montes de Oca M, Pinto-Plata V, Aguirre-Jaime A, Six Minute Walk Distance Project (ALAT): The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J 2011, 37:150-156.
• [18]van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA: A randomized study of alglucosidase alfa in late-onset Pompe’s disease. N Engl J Med 2010, 362:1396-1406.
• [19]Ravaglia S, Pichiecchio A, Ponzio M, Danesino C, Saeidi Garaghani K, Poloni GU, Toscano A, Moglia A, Carlucci A, Bini P, Ceroni M, Bastianello S: Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response. J Inherit Metab Dis 2010, 33:737-745.
• [20]Heresi GA, Dweik RA: Strengths and limitations of the six-minute-walk test: a model biomarker study in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 183:1122-1124.
• [21]Inal-Ince D, Savci S, Arikan H, Saglam M, Vardar-Yagli N, Bosnak-Guclu M, Dogru D: Effects of scoliosis on respiratory muscle strength in patients with neuromuscular disorders. Spine J 2009, 9:981-986.
• [22]Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH: Interpreting small differences in functional status: the Six Minute Walk Test in chronic lung disease patients. Am J Respir Crit Care Med 1997, 155:1278-1282.
• [23]du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr: Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011, 183:1231-1237.
• [24]Gremeaux V, Troisgros O, Benaïm S, Hannequin A, Laurent Y, Casillas JM, Benaïm C: Determining the minimal clinically important difference for the six-minute walk test and the 200-meter fast-walk test during cardiac rehabilitation program in coronary artery disease patients after acute coronary syndrome. Arch Phys Med Rehabil 2011, 92:611-619.
• [25]Mathai SC, Puhan MA, Lam D, Wise RA: The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2012, 186:428-433.
• [26]Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schünemann HJ: Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J 2008, 32:637-643.
• [27]McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Atkinson L, Elfring GL, Reha A, Miller LL: The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 2010, 42:966-974.
• [28]McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, Atkinson L, Reha A, Hirawat S, Miller LL: The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 2010, 41:500-510.
• [29]Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
• [30]Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Swiedler SJ, Kakkis ED, Braakman T, Chadbourne E, Walton-Bowen K, Cox GF: Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004, 144:581-588.
• [31]Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, Deschauer M, Breunig F, Glocker FX, Vielhaber S, Brejova A, Hilz M, Reiners K, Müller-Felber W, Mengel E, Spranger M, Schoser B: Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 2010, 257:91-97.
• [32]Bembi B, Pisa FE, Confalonieri M, Ciana G, Fiumara A, Parini R, Rigoldi M, Moglia A, Costa A, Carlucci A, Danesino C, Pittis MG, Dardis A, Ravaglia S: Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis 2010, 33:727-735.
• [33]Ishigaki K, Murakami T, Nakanishi T, Oda E, Sato T, Osawa M: Close monitoring of initial enzyme replacement therapy in a patient with childhood-onset Pompe disease. Brain Dev 2012, 34:98-102.
• [34]de Vries JM, van der Beek NA, Kroos MA, Ozkan L, van Doorn PA, Richards SM, Sung CC, Brugma JD, Zandbergen AA, van der Ploeg AT, Reuser AJ: High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 2010, 101:338-345.
• [35]Merk T, Wibmer T, Schumann C, Krüger S: Glycogen storage disease type II (Pompe disease)-influence of enzyme replacement therapy in adults. Eur J Neurol 2009, 16:274-277.
• [36]de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M, van Engelen BG, Kuks JB, van der Kooi AJ, Notermans NC, Faber CG, Verschuuren JJ, Kruijshaar ME, Reuser AJ, van Doorn PA, van der Ploeg AT: Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 2012, 7:73. BioMed Central Full Text
• [37]Toscano A, Schoser B: Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 2013, 260:951-959.
• [38]Wells AU, Behr J, Silver R: Outcome measures in the lung. Rheumatology (Oxford) 2008, 47(Suppl 5):v48-v50.
• [39]du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU: Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011, 184:1382-1389.
• [40]Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, Hansell DM, du Bois RM, Wells AU: Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:830-836.
• [41]Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, Wamboldt FS: The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010, 104:296-304.
• [42]Vielhaber S, Brejova A, Debska-Vielhaber G, Kaufmann J, Feistner H, Schoenfeld MA, Awiszus F: 24-months results in two adults with Pompe disease on enzyme replacement therapy. Clin Neurol Neurosurg 2011, 113:350-357.
• [43]de Vries JM, Brugma JD, Ozkan L, Steegers EA, Reuser AJ, van Doorn PA, van der Ploeg AT: First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease. Mol Genet Metab 2011, 104:552-555.
• [44]Furusawa Y, Mori-Yoshimura M, Yamamoto T, Sakamoto C, Wakita M, Kobayashi Y, Fukumoto Y, Oya Y, Fukuda T, Sugie H, Hayashi YK, Nishino I, Nonaka I, Murata M: Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study. J Inherit Metab Dis 2012, 35:301-310.
• [45]Korpela MP, Paetau A, Löfberg MI, Timonen MH, Lamminen AE, Kiuru-Enari SM: A novel mutation of the GAA gene in a Finnish late-onset Pompe disease patient: clinical phenotype and follow-up with enzyme replacement therapy. Muscle Nerve 2009, 40:143-148.
• [46]Van der Beek NA, Hagemans ML, Reuser AJ, Hop WC, Van der Ploeg AT, Van Doorn PA, Wokke JH: Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 2009, 19:113-117.
• [47]Escolar DM, Hache LP, Clemens PR, Cnaan A, McDonald CM, Viswanathan V, Kornberg AJ, Bertorini TE, Nevo Y, Lotze T, Pestronk A, Ryan MM, Monasterio E, Day JW, Zimmerman A, Arrieta A, Henricson E, Mayhew J, Florence J, Hu F, Connolly AM: Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011, 77:444-452.
• [48]Spurney CF, Rocha CT, Henricson E, Florence J, Mayhew J, Gorni K, Pasquali L, Pestronk A, Martin GR, Hu F, Nie L, Connolly AM, Escolar DM, Cooperative International Neuromuscular Research Group Investigators: CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy. Muscle Nerve 2011, 44:174-178.
• [49]Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, McCarter RJ, Escolar DM: Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy. Muscle Nerve 2007, 35:36-42.
• [50]Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, Mayhew J, Tesi-Rocha C, Gorni K, Pasquali L, Patel KM, McCarter R, Huang J, Mayhew T, Bertorini T, Carlo J, Connolly AM, Clemens PR, Goemans N, Iannaccone ST, Igarashi M, Nevo Y, Pestronk A, Subramony SH, Vedanarayanan VV, Wessel H, CINRG Group: CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol 2005, 58:151-155.
• [51]Beenakker EA, Fock JM, Van Tol MJ, Maurits NM, Koopman HM, Brouwer OF, Van der Hoeven JH: Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Arch Neurol 2005, 62:128-132.
• [52]Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J, Manzur A, Muntoni F, North Star Clinical Network for Paediatric Neuromuscular Disease: Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int 2012, 17:101-109.
• [53]Mayhew A, Cano S, Scott E, Eagle M, Bushby K, Muntoni F, North Star Clinical Network for Paediatric Neuromuscular Disease: Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol 2011, 53:535-542.
• [54]Mazzone E, Martinelli D, Berardinelli A, Messina S, D’Amico A, Vasco G, Main M, Doglio L, Politano L, Cavallaro F, Frosini S, Bello L, Carlesi A, Bonetti AM, Zucchini E, De Sanctis R, Scutifero M, Bianco F, Rossi F, Motta MC, Sacco A, Donati MA, Mongini T, Pini A, Battini R, Pegoraro E, Pane M, Pasquini E, Bruno C, Vita G, de Waure C, Bertini E, Mercuri E: North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy. Neuromuscul Disord 2010, 20:712-716.
• [55]Mayhew AG, Eagle M, Scott E, Bushby KM, Adnan M, Muntoni F, Sano SJ: Trial readiness: clinical interpretability of change scores of the North Star Ambulatory Assessment in Duchenne muscular dystrophy [abstract]. Neuromuscul Disord 2012, 22:876-877.
• [56]Vuillerot C, Payan C, Girardot F, Fermanian J, Iwaz J, Bérard C, Ecochard R, MFM Study Group: Responsiveness of the motor function measure in neuromuscular diseases. Arch Phys Med Rehabil 2012, 93:2251-2256.
• [57]Cooperative International Neuromuscular Research Group (CINRG): CQMS advantage. [ http://www.cinrgresearch.org/cinrgnetwork/cqms.cfm webcite]
• [58]Grootenhuis MA, de Boone J, van der Kooi AJ: Living with muscular dystrophy: health related quality of life consequences for children and adults. Health Qual Life Outcomes 2007, 5:31. BioMed Central Full Text
• [59]Vandervelde L, Van den Bergh PY, Renders A, Goemans N, Thonnard JL: Relationships between motor impairments and activity limitations in patients with neuromuscular disorders. J Neurol Neurosurg Psychiatry 2009, 80:326-332.
• [60]Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, Brach J, Chandler J, Cawthon P, Connor EB, Nevitt M, Visser M, Kritchevsky S, Badinelli S, Harris T, Newman AB, Cauley J, Ferrucci L, Guralnik J: Gait speed and survival in older adults. JAMA 2011, 305:50-58.
• [61]Hardy SE, Perera S, Roumani YF, Chandler JM, Studenski SA: Improvement in usual gait speed predicts better survival in older adults. J Am Geriatr Soc 2007, 55:1727-1734.
• [62]Inam S, Vucic S, Brodaty NE, Zoing MC, Kiernan MC: The 10-metre gait speed as a functional biomarker in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010, 11:558-561.
• [63]Claerbout M, Gebara B, Ilsbroukx S, Verschueren S, Peers K, Van Asch P, Feys P: Effects of 3 weeks’ whole body vibration training on muscle strength and functional mobility in hospitalized persons with multiple sclerosis. Mult Scler 2012, 18:498-505.
• [64]Schimpl M, Moore C, Lederer C, Neuhaus A, Sambrook J, Danesh J, Ouwehand W, Daumer M: Association between walking speed and age in healthy, free-living individuals using mobile accelerometry–a cross-sectional study. PLoS One 2011, 6:e23299.
• [65]Motl RW, Weikert M, Suh Y, Sosnoff JJ, Pula J, Soaz C, Schimpl M, Lederer C, Daumer M: Accuracy of the actibelt(®) accelerometer for measuring walking speed in a controlled environment among persons with multiple sclerosis. Gait Posture 2012, 35:192-196.
• [66]Wood M, Cleary MA, Alderson L, Velllodi A: Changes in gait pattern as assessed by the GAITRite™ walkway system in MPS II patients undergoing enzyme replacement therapy. J Inherit Metab Dis 2009, 32(Suppl 1):S127-S135.
• [67]Pickett KA, Duncan RP, Hoekel J, Marshall B, Hershey T, Earhart GM, Washington University Wolfram Study Group: Early presentation of gait impairment in Wolfram Syndrome. Orphanet J Rare Dis 2012, 7:92. BioMed Central Full Text
• [68]Sosnoff JJ, Weikert M, Dlugonski D, Smith DC, Motl RW: Quantifying gait impairment in multiple sclerosis using GAITRite technology. Gait Posture 2011, 34:145-147.
• [69]Devy R, Lehert P, Varlan E, Genty M, Edan G: A short and validated multiple sclerosis-specific health-related quality of life measurement for routine medical practice. Eur J Neurol 2013, 20:935-941.
• [70]Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A: The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci 1999, 169:13-21.
• [71]Nève V, Cuisset JM, Edmé JL, Carpentier A, Howsam M, Leclerc O, Matran R: SNIP interest in the longitudinal assessment of young Duchenne muscular dystrophy children. Eur Respir J 2012. doi:10.1183/09031936.00127712
• [72]Hobson-Webb LD, Jones HN, Kishnani PS: Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement. Neuromuscul Disord 2013, 23:319-323.
• [73]Prigent H, Orlikowski D, Laforèt P, Letilly N, Falaize L, Pellegrini N, Annane D, Raphael JC, Lofaso F: Supine volume drop and diaphragmatic function in adults with Pompe disease [letter]. Eur Respir J 2012, 39:1545-1546.
• [74]Vianello A, Semplicini C, Paladini L, Concas A, Ravaglia S, Servidei S, Toscano A, Mongini T, Angelini C, Pegoraro E: Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency. Lung 2013, 191:537-544.
• [75]Angelini C, Semplicini C, Ravaglia S, Moggio M, Comi GP, Musumeci O, Pegoraro E, Tonin P, Filosto M, Servidei S, Morandi L, Crescimanno G, Marrosu G, Siciliano G, Mongini T, Toscano A, the Italian Group on GSDII: New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy. Muscle Nerve 2012, 45:831-834.
• [76]van der Beek NA, Hagemans ML, van der Ploeg AT, van Doorn PA, Merkies IS: The Rasch-built Pompe-specific Activity (R-PAct) scale. Neuromuscul Disord 2013, 23:256-264.